The Technical Analyst
G1 Therapeutics Inc [GTHX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
G1 Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.57% $4.17
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 217.67 mill |
| EPS: | -0.930 |
| P/E: | -4.48 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 52.20 mill |
| Avg Daily Volume: | 1.355 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.48 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.76x |
| Company: PE -4.48 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.81 - 4.53 ( +/- 8.54%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-20 | Thomas Monica R. | Buy | 37 500 | Common Stock |
| 2024-03-20 | Avagliano Mark | Buy | 100 000 | Common Stock |
| 2024-03-20 | Umstead John W. V | Buy | 37 500 | Common Stock |
| 2024-03-18 | Umstead John W. V | Sell | 6 547 | Common Stock |
| 2024-02-12 | Malik Rajesh | Buy | 28 600 | Common Stock |
| INSIDER POWER |
|---|
| 72.72 |
| Last 100 transactions |
| Buy: 2 421 369 | Sell: 357 781 |
Forecast:
16:00 - $4.17
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.17
Forecast 2: 16:00 - $4.17
Forecast 3: 16:00 - $4.17
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.17 (-2.57% ) |
| Volume | 0.688 mill |
| Avg. Vol. | 1.355 mill |
| % of Avg. Vol | 50.73 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GTHX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.75 | N/A | Active |
|---|
GTHX
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Latest Press Releases
2024-04-17 09:00:00 - Press Release
G1 Therapeutics To Release First Quarter 2024 Financial Results And Provide Business update On May 1, 2024
Research triangle park, n.c., april 17, 2024 (globe newswire) -- g1 therapeutics, inc. (nasdaq: gthx ), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on wednesday may 1, 2024, at 8:30 a.m.
2024-04-04 10:30:00 - Press Release
G1 Therapeutics To Participate In The 23rd Annual Needham Virtual Healthcare Conference
Research triangle park, n.c., april 04, 2024 (globe newswire) -- g1 therapeutics, inc. (nasdaq: gthx), a commercial-stage oncology company, today announced that g1's chief executive officer jack bailey will provide a corporate presentation during the 23rd annual needham virtual healthcare conference on thursday, april 11, 2024, at 8:45 am et.
2024-04-01 16:20:00 - Press Release
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Research triangle park, n.c., april 01, 2024 (globe newswire) -- g1 therapeutics, inc. (nasdaq: gthx), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 3,000 shares of g1's common stock and 1,500 restricted stock units (rsus) to one hired employee under the amended and restated g1 therapeutics, inc. 2021 inducement equity incentive plan (the “amended and restated 2021 plan”).
2024-03-01 16:20:00 - Press Release
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Research triangle park, n.c., march 01, 2024 (globe newswire) -- g1 therapeutics, inc. (nasdaq: gthx), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 shares of g1's common stock and 1,050 restricted stock units (rsus) to one hired employee under the amended and restated g1 therapeutics, inc. 2021 inducement equity incentive plan (the “amended and restated 2021 plan”).
2024-02-28 06:30:00 - Press Release
G1 Therapeutics Provides Fourth Quarter And Full Year 2023 Financial Results And Operational Highlights
- achieved $46.3 million in net revenue from sales of cosela® (trilaciclib) for full year 2023, representing 48% growth over 2022; provided 2024 net cosela revenue guidance of $60 to $70 million - - net cosela revenue grew 29% in the fourth quarter of 2023 to $13.9 million - - announced that final analysis of phase 3 preserve 2 trial evaluating overall survival in metastatic triple negative breast cancer is estimated to occur in the third quarter of 2024 - - presented new analyses indicating that patients who previously received trilaciclib in a clinical trial setting experienced improved overall survival with subsequent anticancer therapies - - provided initial results from phase 2 trial in combination with a trop2 antibody-drug conjugate indicating improvements in overall survival for patients receiving trilaciclib - - management to host webcast and conference call today at 8:30 am et - research triangle park, n...
Latest News
2024-04-17 09:00:00 - GlobeNewsWire
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m.
2024-03-22 17:51:46 - Seeking Alpha
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with Extensive-Stage Small Cell Lung Cancer. The company's research pipeline includes exploring new indications for Trilaciclib in breast and bladder cancer, reporting a 29% increase in Cosela's net revenues in Q4 2023.
2024-02-28 08:41:16 - Zacks Investment Research
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
G1 Therapeutics (GTHX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.73 per share a year ago.
2024-02-15 08:30:00 - GlobeNewsWire
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the fourth quarter and full year 2023 on Wednesday February 28, 2024, at 8:30 a.m.
2024-02-13 08:15:26 - InvestorPlace
Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?
G1 Therapeutics (NASDAQ: GTHX ) stock is falling hard on Tuesday after the biopharmaceutical company provided an interim update on a Phase 3 clinical trial of trilaciclib as a breast cancer treatment. This clinical trial has trilaciclib being used in combination with gemcitabine and carboplatin as a first line treatment for metastatic triple negative breast cancer (mTNBC).
2024-01-09 07:55:26 - Seeking Alpha
G1 Therapeutics: New Financials And Big Data Readout Alert
G1 Therapeutics has provided pipeline updates, including encouraging preliminary overall survival data from a phase 2 study of trilaciclib in combination with sacituzumab govitecan for advanced triple-negative breast cancer. The company aims to pursue global partnerships for the release and support of trilaciclib if positive results are obtained from the ongoing trials. G1 Therapeutics' cash runway has been extended into early 2025, providing more time to address FDA filings and potential partnerships.
2023-12-06 14:48:10 - PennyStocks
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.
2023-11-01 12:25:28 - Seeking Alpha
G1 Therapeutics, Inc. (GTHX) Q3 2023 Earnings Call Transcript
G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Will Roberts – Vice President-Communications Jack Bailey – Chief Executive Officer Andrew Perry – Chief Commercial Officer Raj Malik – Chief Medical Officer John Umstead – Chief Financial Officer Conference Call Participants Gil Blum – Needham & Company Dane Leone – RJF Anupam Rama – JPMorgan Troy Langford – TD Cowen Operator Good day and thank you for standing by. Welcome to the G1 Therapeutics Third Quarter 2023 Financial Results Call.
2023-10-31 14:18:58 - PennyStocks
Penny Stocks To Buy Today? 4 To Watch Now
Ready to dive into the volatile world of penny stocks? You've got your work cut out for yourself if this is your first foray into the stock market.
2023-09-05 11:00:00 - GlobeNewsWire
G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference.